Your browser is no longer supported. Please, upgrade your browser.
Settings
REGN Regeneron Pharmaceuticals, Inc. daily Stock Chart
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E22.53 EPS (ttm)16.61 Insider Own0.50% Shs Outstand107.53M Perf Week1.49%
Market Cap40.24B Forward P/E17.03 EPS next Y21.98 Insider Trans-26.19% Shs Float75.55M Perf Month1.77%
Income1.92B PEG2.25 EPS next Q5.10 Inst Own71.60% Short Float3.70% Perf Quarter24.01%
Sales6.20B P/S6.49 EPS this Y70.80% Inst Trans2.46% Short Ratio3.47 Perf Half Y12.68%
Book/sh66.66 P/B5.61 EPS next Y8.01% ROA17.30% Target Price406.05 Perf Year-19.34%
Cash/sh15.66 P/C23.91 EPS next 5Y10.00% ROE24.50% 52W Range281.89 - 505.49 Perf YTD-0.45%
Dividend- P/FCF24.59 EPS past 5Y14.30% ROI22.30% 52W High-25.96% Beta1.20
Dividend %- Quick Ratio3.10 Sales past 5Y33.60% Gross Margin93.30% 52W Low32.77% ATR9.20
Employees6200 Current Ratio3.60 Sales Q/Q9.40% Oper. Margin36.90% RSI (14)54.60 Volatility2.11% 2.57%
OptionableYes Debt/Eq0.00 EPS Q/Q44.30% Profit Margin25.70% Rel Volume0.81 Prev Close371.78
ShortableYes LT Debt/Eq0.10 EarningsAug 02 BMO Payout0.00% Avg Volume806.15K Price374.26
Recom2.60 SMA20-0.03% SMA505.61% SMA2007.43% Volume650,605 Change0.67%
May-04-18Reiterated Canaccord Genuity Hold $356 → $304
Apr-09-18Downgrade Raymond James Outperform → Mkt Perform
Feb-21-18Downgrade Canaccord Genuity Buy → Hold $522 → $356
Jan-09-18Reiterated Citigroup Neutral $380 → $388
Dec-01-17Downgrade Citigroup Buy → Neutral $480 → $380
Nov-09-17Reiterated RBC Capital Mkts Sector Perform $473 → $425
Oct-24-17Resumed Guggenheim Buy $540
Oct-20-17Downgrade Barclays Equal Weight → Underweight $450 → $395
Sep-29-17Resumed Piper Jaffray Overweight $540
Sep-15-17Initiated RBC Capital Mkts Sector Perform $475
Sep-06-17Resumed Raymond James Outperform $566
Aug-17-17Initiated Evercore ISI Outperform $605
Aug-04-17Reiterated UBS Buy $489 → $535
Aug-01-17Downgrade Robert W. Baird Neutral → Underperform $408
Jun-30-17Reiterated BTIG Research Buy $480 → $540
Jun-26-17Downgrade Bernstein Outperform → Mkt Perform
Jun-20-17Reiterated Piper Jaffray Overweight $446 → $557
May-05-17Upgrade Canaccord Genuity Hold → Buy $375 → $484
Mar-29-17Reiterated UBS Buy $435 → $446
Mar-17-17Initiated Oppenheimer Perform
Aug-17-18 01:55PM  Edited Transcript of REGN earnings conference call or presentation 2-Aug-18 12:30pm GMT Thomson Reuters StreetEvents
09:01AM  Regeneron, Teva Announce Positive Data on Osteoarthritis Drug Zacks
07:51AM  Regeneron's anti-blindness drug approved for less frequent treatments Reuters
07:00AM  FDA Approves EYLEA® (aflibercept) Injection sBLA in Wet Age-related Macular Degeneration PR Newswire
Aug-16-18 07:00AM  Teva and Regeneron Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip Business Wire
07:00AM  Regeneron and Teva Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip PR Newswire
Aug-14-18 09:49AM  Regeneron's 12-Week Eylea Dose Gets CRL From FDA for Wet AMD Zacks
08:43AM  Time to Focus on Regeneron Pharmaceuticals (REGN) for Strong Earnings Growth Potential Zacks
Aug-13-18 05:00PM  Know This Sell Signal: When Stock Leaders Stage Big Downside Reversals Investor's Business Daily
07:00AM  Regeneron Provides Regulatory Update on EYLEA® (aflibercept) Injection sBLA in Wet Age-Related Macular Degeneration PR Newswire
Aug-09-18 10:25PM  Carl Icahn Fires Shots at Express Scripts Motley Fool
02:50PM  7 "Zombie Stocks" That Are Coming Back to Life Kiplinger
Aug-08-18 07:52AM  Biotech Stock Roundup: Regeneron Shines, BLUE Surges, ONCE Plunges Zacks
Aug-07-18 11:30AM  Why this company's Durham outpost may benefit from $100M investment American City Business Journals
Aug-06-18 04:15PM  Can These Biotech Companies Catch Novartis, Gilead In CAR-T? Investor's Business Daily
01:30PM  T-Mobile-Sprint, Pepsi CEO Departs, Jamie Dimon's Latest Wisdom, & More | Free Lunch Zacks
11:59AM  Small Biotechs See Big Gains as Bluebird, Intercept Fly Barrons.com
11:44AM  Why Is Bluebird Bio (BLUE) Stock Gaining Today? Zacks
11:02AM  Regeneron To Make $100M bluebird bio Investment In Cancer Research Collaboration Benzinga
09:39AM  Bluebird Bio stock lifts on Regeneron collaboration, $100 mln investment MarketWatch
06:30AM  Regeneron and bluebird bio Announce Collaboration to Discover, Develop and Commercialize New Cell Therapies for Cancer PR Newswire
06:30AM  bluebird bio and Regeneron Announce Collaboration to Discover, Develop and Commercialize New Cell Therapies for Cancer Business Wire
Aug-03-18 09:33AM  Company News For Aug 3, 2018 Zacks
08:49AM  Regeneron Pharmaceuticals (REGN) Jumps: Stock Rises 7% Zacks
07:30AM  Regeneron Announces the 2018 Winners of the Regeneron Prize for Creative Innovation PR Newswire
Aug-02-18 04:13PM  Can Regeneron Stock Hit $400 For The First Time This Year? Investor's Business Daily +7.00%
03:48PM  Zoetis (ZTS) Beats on Q2 Earnings & Sales, Updates '18 View Zacks
03:09PM  Regeneron Soars After My 'Go Long' Recommendation: What Now? TheStreet.com
12:05PM  Dow Jones Falls On Trade War Fears; Tesla Stock Buoys Nasdaq Investor's Business Daily
11:35AM  Regeneron (REGN) Q2 Earnings Beat on Strong Dupixent Sales Zacks
11:06AM  Regeneron posts quarterly profit beat, strongly backs Eylea's future Reuters
08:05AM  Stocks making the biggest moves premarket: DWDP, TSLA, NKE, SBUX, YUM & more CNBC
08:00AM  Regeneron (REGN) Q2 Earnings and Revenues Beat Estimates Zacks
07:00AM  Regeneron profit beats expectations on sales of eczema drug Reuters
06:53AM  Regeneron: 2Q Earnings Snapshot Associated Press
06:30AM  Regeneron Reports Second Quarter 2018 Financial and Operating Results PR Newswire
Aug-01-18 03:46PM  Regeneron Pharmaceuticals Earnings Outlook Benzinga
10:48AM  Drug Stock Q2 Earnings Releases on Aug 2: ZTS, REGN & More Zacks
Jul-31-18 12:05PM  Why Sanofi Stock Should Run Higher Despite Mixed Earnings InvestorPlace
09:26AM  Zoetis (ZTS) Gears Up for Q2 Earnings: What's in Store? Zacks
Jul-30-18 05:47PM  Regeneron (REGN) to Report Q2 Earnings: What's in the Cards? Zacks
Jul-27-18 09:30AM  REGN vs. LGND: Which Stock Should Value Investors Buy Now? Zacks
08:25AM  Recent Analysis Shows Ameriprise Financial, Covenant Transportation Group, Popular, Suburban Propane Partners, AAC, and Regeneron Pharmaceuticals Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Jul-26-18 06:05PM  How to Invest at Every Age: Cramer's 'Mad Money' Recap (Thursday 7/26/18) TheStreet.com
Jul-24-18 01:25PM  NYSE trader: Amazon, Visa and Twitter earnings are on my radartheir charts are very similar Yahoo Finance Video
Jul-23-18 05:47PM  Whats Next for Pfizer Stock After Being Called Out by President Trump InvestorPlace
06:00AM  3 Hot Biotech Stocks With More Gains Ahead Investopedia
Jul-19-18 07:05AM  Free Technical Reports on Portola Pharma and Three Additional Biotech Equities ACCESSWIRE
Jul-17-18 12:33PM  GlaxoSmithKline Is More Than Just a 5% Dividend Income Play InvestorPlace
Jul-09-18 09:30AM  Regeneron to Report Second Quarter 2018 Financial and Operating Results and Host Conference Call and Webcast on August 2, 2018 PR Newswire
Jul-06-18 08:01PM  3 Top Biotech Stocks to Buy in July Motley Fool
05:29PM  Is health care the ultimate hideout trade? CNBC Videos
Jul-02-18 04:38PM  Upside 'Substantial' As Regeneron Ups Price On Blockbuster Hopeful Investor's Business Daily
02:00PM  Biotech Regeneron Seen Rising 13% on Better Outlook Investopedia
Jun-29-18 08:03AM  3 Big Stock Charts for Friday: Sherwin-Williams, Regeneron and Allstate InvestorPlace
Jun-28-18 01:57PM  Regeneron, McKesson, AmerisourceBergen, FedEx & Hilton CNBC Videos
Jun-27-18 11:09AM  Regeneron: 'On the Cusp' of Big Sales Growth Barrons.com
Jun-26-18 06:59PM  How to Invest at Every Age: Cramer's 'Mad Money' Recap (Tuesday 6/26/18) TheStreet.com
Jun-22-18 02:24PM  Did Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Create Value For Shareholders? Simply Wall St.
Jun-20-18 08:00AM  Today's Research Reports on Trending Tickers: Regeneron Pharmaceuticals and Intrexon ACCESSWIRE
02:02AM  Latecomer Sanofi looks to catch next wave of cancer therapies Reuters
Jun-13-18 10:34AM  Biotech Stock Roundup: AXON Soars, Amgen Drugs Get FDA, EC Nod Zacks
Jun-08-18 07:10AM  Blog Exposure - Regeneron Inks Five-Year Collaboration Deal with Zoetis to Discover Antibody Therapies in Animal Health ACCESSWIRE
Jun-07-18 10:42AM  The Bull Case for Regeneron Pharmaceuticals Inc Couldnt Be More Clear InvestorPlace
Jun-06-18 08:31AM  Biotech Stock Roundup: Regeneron, Celgene, Amgen Impress at ASCO Zacks
07:00AM  Regeneron and Zoetis Announce Collaboration to Research Antibody Therapies for Use in Animal Health PR Newswire
Jun-05-18 07:01PM  New Ebola Outbreak May Open Door to Finding Drugs Bloomberg
01:38PM  Where Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Stands In Terms Of Earnings Growth Against Its Industry Simply Wall St.
Jun-04-18 02:17PM  Sanofi: New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma GlobeNewswire
02:15PM  New England Journal of Medicine Publishes Pivotal Cemiplimab Trials Showing Positive Results in Advanced Cutaneous Squamous Cell Carcinoma PR Newswire
02:15PM  New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma PR Newswire
06:20AM  Why Is Regeneron Pharmaceuticals (REGN) Up 2.7% Since Its Last Earnings Report? Zacks
Jun-01-18 12:58PM  Aggressive Traders Must Go Long Regeneron Pharmaceuticals TheStreet.com
07:38AM  Jim Cramer Shares His Thoughts On Lululemon, Regeneron And More Benzinga
May-31-18 08:35PM  Cramer's lightening round: I wouldn't be shocked if Sanof... CNBC Videos
04:05PM  Regeneron's Investigational Ebola Treatment Shipping to Democratic Republic of the Congo for Use in Current Outbreak PR Newswire
May-30-18 01:33PM  Trump says drugmakers are going to announce massive voluntary price cuts in two weeks CNBC
May-23-18 02:29PM  Biotech Stock Roundup: FDA Gives Nod to Amgen's Drugs, EU Approves Exelixis' Cabometyx Zacks
May-22-18 01:39PM  Is Regeneron Pharmaceuticals Incs (NASDAQ:REGN) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St.
May-21-18 02:17PM  Sanofi: New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent® (dupilumab) improved moderate-to-severe asthma GlobeNewswire
02:15PM  New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent® (dupilumab) improved moderate-to-severe asthma PR Newswire
02:14PM  New England Journal of Medicine Publishes Two Positive Phase 3 Trials Showing DUPIXENT® (dupilumab) Improved Moderate-to-Severe Asthma PR Newswire
May-18-18 09:30AM  Regeneron Announces Upcoming Investor Conference Presentation PR Newswire
May-17-18 04:41PM  Regeneron: Too 'Legit' To Quit Vs. Merck, Bristol In Lung Cancer Investor's Business Daily
10:00AM  Amgen's (AMGN) Repatha Gains EU Nod to Include Outcomes Data Zacks
May-16-18 05:00PM  Regeneron and Sanofi Share First Positive Clinical Data for Cemiplimab in Advanced Non-small Cell Lung Cancer at ASCO PR Newswire
02:37PM  MARKETS: Russell 2000 hits all-time high; Walmart earnings on deck; oil prices reverse; healthcare stocks in focus Yahoo Finance Video
11:00AM  Sanofi Eczema Drug Dupixent Succeeds in Adolescents Study Zacks
08:00AM  Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis PR Newswire
01:01AM  Sanofi: Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis GlobeNewswire
01:01AM  Positive Phase 3 Trial of DUPIXENT® (dupilumab) in Adolescents with Inadequately Controlled Moderate-to-severe Atopic Dermatitis PR Newswire
May-14-18 08:00AM  Todays Research Reports on Stocks to Watch: Regeneron Pharmaceuticals and Synergy Pharmaceuticals ACCESSWIRE
May-11-18 04:36PM  Why The Trade Desk, Noodles & Co., and Regeneron Pharmaceuticals Jumped Today Motley Fool +6.24%
02:08PM  Regeneron Downtrend Ending But No Rush to Buy TheStreet.com
May-10-18 06:31PM  Cramer vets biotech giants Biogen, Celgene, Gilead and Regeneron for positive prospects CNBC
May-08-18 04:15PM  Edited Transcript of REGN earnings conference call or presentation 3-May-18 12:30pm GMT Thomson Reuters StreetEvents
May-07-18 11:34AM  Geisinger to offer DNA sequencing to all its patients American City Business Journals
May-06-18 09:22AM  3 Reasons Regeneron Stock Could Start Climbing Again Motley Fool
May-05-18 09:16AM  2 Beaten-Down Biotech Stocks That Look Like Bargains Now Motley Fool
07:31AM  Are These Disappointing Drugs Back on Track to Billions? Motley Fool
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat adult patients with moderate-to-severe atopic dermatitis; Praluent injection, an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and Kevzara solution for subcutaneous injection to treat rheumatoid arthritis in adults. In addition, the company offers ARCALYST injection for cryopyrin-associated periodic syndromes; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. Further, it develops EYLEA, a trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma; and Dupixent, Praluent, Kevzara, Suptavumab, Cemiplimab, Fasinumab, Evinacumab, Nesvacumab/aflibercept, Trevogrumab, REGN1908-1909, REGN1979, REGN3470-3471-3479, REGN2477, REGN3500, REGN3767, and REGN3918, which are antibody-based clinical programs under various stages of development. The company has collaboration and license agreements with Sanofi, Bayer, Mitsubishi Tanabe Pharma, Teva, Intellia Therapeutics, Adicet Bio, Decibel Therapeutics, Astellas, Alnylam Pharmaceuticals, Inc., bluebird bio, Inc., and others. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GOLDSTEIN JOSEPH LDirectorAug 02Option Exercise57.112,000114,22014,000Aug 03 04:03 PM
GOLDSTEIN JOSEPH LDirectorAug 02Sale380.002,000760,00012,000Aug 03 04:03 PM
VAGELOS P ROYChairman of the BoardJul 10Sale367.2274,67027,420,277399,847Jul 11 04:04 PM
VAGELOS P ROYChairman of the BoardJul 09Option Exercise16.80153,2742,575,003553,121Jul 11 04:04 PM
GOLDSTEIN JOSEPH LDirectorJul 06Option Exercise57.112,000114,22014,000Jul 09 04:04 PM
GOLDSTEIN JOSEPH LDirectorJul 06Sale370.002,000740,00012,000Jul 09 04:04 PM
GOLDSTEIN JOSEPH LDirectorJul 05Option Exercise57.112,000114,22014,000Jul 09 04:04 PM
GOLDSTEIN JOSEPH LDirectorJul 05Sale360.002,000720,00012,000Jul 09 04:04 PM
VAGELOS P ROYChairman of the BoardJun 21Sale327.8774,71024,495,410399,847Jun 22 04:03 PM
VAGELOS P ROYChairman of the BoardJun 20Option Exercise16.80153,2742,575,003553,121Jun 22 04:03 PM
STAHL NEILEVP Research and DevelopmentMay 24Sale295.0911,4073,366,09231,973May 25 04:03 PM
STAHL NEILEVP Research and DevelopmentMay 23Option Exercise30.6326,736818,92458,709May 25 04:03 PM
SING GEORGE LDirectorMay 10Sale286.6213,0003,726,000114,772May 11 04:02 PM
SING GEORGE LDirectorMay 09Sale285.297,0001,997,030127,772May 11 04:02 PM
GOLDSTEIN JOSEPH LDirectorMar 19Option Exercise57.112,000114,22014,000Mar 19 04:47 PM
GOLDSTEIN JOSEPH LDirectorMar 19Sale350.022,000700,04012,000Mar 19 04:47 PM
GOLDSTEIN JOSEPH LDirectorMar 14Option Exercise57.112,000114,22014,000Mar 14 04:01 PM
GOLDSTEIN JOSEPH LDirectorMar 14Sale340.002,000680,00012,000Mar 14 04:01 PM
GOLDSTEIN JOSEPH LDirectorFeb 09Sale325.601,000325,60012,000Feb 13 04:01 PM
Fenimore Christopher R.VP ControllerJan 16Option Exercise21.251503,188150Jan 17 04:07 PM
SING GEORGE LDirectorJan 02Option Exercise23.8415,000357,600134,772Jan 03 04:13 PM
YANCOPOULOS GEORGEPresident & CSODec 13Option Exercise21.92195,4384,284,001786,786Dec 13 05:17 PM
SCHLEIFER LEONARD SPresident & CEODec 13Option Exercise21.92250,0005,480,000407,409Dec 13 05:17 PM
VAGELOS P ROYChairman of the BoardDec 11Option Exercise21.92153,9693,375,000483,512Dec 13 04:53 PM
BROWN MICHAEL SDirectorOct 05Option Exercise177.821,500266,7301,500Oct 05 04:18 PM
BROWN MICHAEL SDirectorOct 05Sale475.001,500712,5000Oct 05 04:18 PM
BAKER CHARLES ADirectorSep 29Option Exercise18.612,00037,22011,000Oct 03 04:00 PM
BAKER CHARLES ADirectorSep 29Sale450.002,000900,0009,000Oct 03 04:00 PM
Landry Robert ESVP Finance & CFOSep 06Sale497.62474235,8737,099Sep 06 05:06 PM
Landry Robert ESVP Finance & CFOSep 05Sale501.0618994,7007,573Sep 06 05:06 PM
Landry Robert ESVP Finance & CFOSep 01Option Exercise272.703,000818,10010,099Sep 06 05:06 PM
Landry Robert ESVP Finance & CFOAug 31Sale493.43427210,6937,099Sep 01 04:04 PM
Landry Robert ESVP Finance & CFOAug 30Option Exercise272.702,000545,4009,099Sep 01 04:04 PM
Landry Robert ESVP Finance & CFOAug 23Sale476.45468222,9817,099Aug 24 04:47 PM
Landry Robert ESVP Finance & CFOAug 22Option Exercise272.702,000545,4009,099Aug 24 04:47 PM
VAGELOS P ROYChairman of the BoardAug 22Sale477.6431,94415,257,816329,543Aug 23 04:21 PM
VAGELOS P ROYChairman of the BoardAug 21Sale470.3224,26911,414,076361,487Aug 23 04:21 PM